Braveheart's $383M IPO Read in browser

Thank you for reading, dupa dupackia! basic Subscription UPGRADE

M T W Thu F 6 August, 2026

One night, one room: the founders, scientists and investors behind the Endpoints 11, together in Boston this September. Reserve your spot now and save with the early bird rate.

presented by Why Amer­i­ca's med­i­cine be­came a na­tion­al se­cu­ri­ty ques­tion

news Braveheart lands $383M IPO to take Hengrui cardio drug into Phase 3 Let the orexin market begin: Takeda snags FDA approval for narcolepsy type 1 drug Greg Verdine’s LifeMine raises $263M for safer immunosuppressant Vedanta gets $60M to finish Phase 3 for C. diff microbiome therapy Revolution Medicines preps for pancreatic drug launch, boosting expected 2026 expenses FDA approves Moderna flu vaccine after spat with past agency leaders Senate confirms Erica Schwartz as CDC director

Aug 19 1:00 pm ET From pilots to production: AI across R&D, safety, regulatory, and clinical sponsored by IBM Aug 27 12:00 pm ET Same molecule, different paths: Where value goes in cross-border dealmaking in a new era sponsored by PharmCube Sep 03 11:00 am ET How leading pharma organizations are putting AI agents to work sponsored by Medable

Scientist, Drug Discovery Data for AI/ML D. E. Shaw Research New York, NY, USA Machine Learning Researchers and Engineers D. E. Shaw Research New York, NY, USA Recruit talent with Endpoints Careers Contact Meg Estacio: mestacio@endpointsnews.com

The China biotech story is moving fast. On Aug. 6, Endpoints hosts debate-style panels on how China's rise is forcing biotech to rethink innovation, live in Boston. Space is limited. Reserve your spot now.

ENDPOINTS PHARMA Demis Hassabis says he's 'leaning into' Isomorphic role amid Alphabet and DeepMind shakeup In a first, WuXi AppTec tops Lonza’s six-month revenue despite Pentagon scrutiny Atossa Therapeutics founder to be selected as NIAID director — report Fujifilm’s Lars Petersen exits, hands leadership baton to COO Maja Pedersen Lilly beats forecasts again as tirzepatide makes up nearly two-thirds of revenue

in case you missed it 1. Merger talks between AstraZeneca, Bristol Myers are off — report 2. Novo Nordisk eyes bolt-on deals as pipeline disappointments pile up